upgrad ow consist execut
past year weve seen signific turnaround perform
manag deliv four consecut beat rais
quarter top bottom-lin out-performance return consist
exceed expect importantli materi improv
gener stick point mani investor next
month believ medtron grow least line end-market
growth plu see number underappreci data present
transform new product launch appear fulli appreci
street modestli rais estim conserv
leav potenti catalyst discuss upsid vs forecast
manag appropri set conserv bar top-lin
earn progress june analyst day see meaning upsid street
estim potenti multipl expans sustain execut
upgrad ow rais ye pt ep
next month continu stream new
product launch signific data present notabl
highlight tyrx wrap-it studi result earli data
on-going extravascular implant possibl hr may
indic expans late miniatur micra av
pacemak address patient afford
major competit advantag asp premium matur pacemak
market launch next-gen linq ii like hr new deep
brain stimul db platform sens hybrid-
close loop insulin pump system correct bolus walk
full pipelin new product launch data set
improv consist execut materi step-up
gener thesi fundament chang invest
lead innov multi-year runway growth upsid
follow multi-year period inconsist execut follow covidien
acquisit share under-perform broader group vs
basi today see inflect point
overal end-market growth improv
compani posit take meaning share larg market
technolog innov follow solid year execut
greater confid manag deliv promis target
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
asid excit pipelin execut improv
appropri expect begin biennial analyst day june
shift investor perspect toward beat-and-rais cultur
manag long-rang target organ sale growth report
ep growth handili beat organ top-lin easi comp
report ep set grow believ
valuat price-to-earnings vs peer improv sustain
 see medtron lrp goal annual
expans achiev like beatabl faster top-lin growth sinc
issu revis oper margin expans target annual
basi versu overli ambiti five-year span issu
analyst day exceed goal
guid constant currenc
oper margin expans full fiscal year look ahead continu
see reason goal like beatabl better organ
revenu growth posit mix impact pipelin technolog move
develop commerci stage increas high-margin cgm attach rate
insulin pump one exampl
sever year under-perform start deliv
commit trend expect continu past
three year experienc number one-tim headwind
notabl payment ir puerto rico tax resolut last year
result gener highli variabl
result below-p convers /adjust ni
vs peer best-in-class peer ytd
medtron alreadi gener track
deliv fy y/i convers go forward
expect improv futur grow least
line earn manag reiter commit investor return
minimum sharehold bulk covidien
debt paydown complet wed expect return focu
like bolt-on size transform
innov hotb largest busi cardiac
vascular group cvg account sale although
cvg group histor associ organ growth
corpor averag leadership posit larg commodit
icd increas see area upsid robust near- longer-
term product pipelin support number potenti catalyst clinic
view arguabl underappreci opportun medtron
today increas util micra leadless pacemak near-term
indic expans pacemak patient signific asp
premium highli like medtron micra pacemak repres meaning
innov one oldest med-tech market year long face
annual price pressur due commodit natur devic
oligopoli less one-tenth size tradit pacemak micra
attach directli patient heart minim invas transcathet
procedur elimin need lead wire tradit pacemak
deliv electr impuls canist heart surgic
procedur creat pocket skin tradit sit
design expect drive better long-term outcom patient lower
infect risk support endur movement med-tech toward
minim invas solut accordingli micra command asp
premium compar pacemak current single-chamb version
sell versu tradit devic
today micra vr address pacemak popul
micra av could approv earli open anoth
market medtron first version micra micra vr approv
april single-chamb pace sens left ventricl
indic encompass overal annual pacemak volum next
iter micra av design dual-chamb sens atrioventricular
av block synchron pace repres largest four patient
subgroup volum last may compani present proof-of-concept
data annual heart rhythm societi hr meet give
compani high degre confid eventu receiv fda approv
indic time-frame follow expans
abl offer micra half popul need
pacemak like wont see data present micra av
approv proof-of-concept data present hr elimin greatest
technic challeng av data posit see high degre
probabl micra av gain approv
due micra tradit pacer asp degre share gain even
cannib exit share drive disproportion revenu
upsid demonstr recent uptick micra util
doctor train drive us pacemak growth
octob also note micra higher asp support differenti
reimburs year start make
real impact procedur growth believ micra sale track /-
calendar see quickli grow multi-hundred-
million dollar annual revenu contribut expans av popul
beyond micra av discuss micra ar ad anoth
address pacemak popul micra ad last
opportun beyond time-frame gradual ramp meaning
higher price premium function product drive share
gain global share today even pronounc outsiz
revenu growth declin market year come
forecast our/street model
near-term horizon see result wrap-it studi
tyrx antibacteri envelop march medtron tyrx
product neuro absorb antibacteri envelop encapsul canist
pacemak product first implant help prevent infect
see result wrap-it studi
random control trial patient evalu cardiac implantable-
relat infect month tyrx-us arm versu control arm
wrap-it show statist signific benefit use tyrx
see studi could potenti chang societi guidelin certain
type patient medtron benefit would two-fold
asp tyrx pouch use margin accret product
drive share gain flat low-singl digit declin market key
provid infect risk guarante reimburs
cost infect hospit one occur hospit receiv
guarante tyrx implant use therefor
highli differenti infect prevent offer drive share
less-differenti space also highlight current
experienc trough replac cycl impact ex-
tyrx/wrap-it turn headwind tailwind easi comp like
late calendar time-frame street dont forecast
materi out-performance tyrx view sourc potenti
also alreadi much front mind investor see
data edward risk tavr studi main
event year devic side present
medtron edward trial evalu tavr valv
surgeri treat low surgic risk cohort expect
trial alreadi favor base registri data parner ii/surtavi
meta-analys risk sub-set think result degre
upsid alreadi bake invest commun market model regardless
continu see tavr import growth driver cvg unit
one fastest-grow end-market beyond risk tavr also
potenti expand asymptomat sever aortic stenosi moder aortic
stenosi heart failur popul could help sustain above-compani
medtron extravascular could potenti game changer
although still number unknown around opportun
cardiovascular rhythm manag divis earli
develop phase extravascular ev featur lead place
outsid heart vein benefit design minim
invas natur smaller size vs compar cut edg
product space today s-icd importantli ev-icd
full atp bradi support pace two option s-icd lack
ev-icd featur painless termin arrhythmia via singl lead outsid
heart vs s-icd termin often pain tradit
icd requir lead pass heart term clinic timelin
ev-icd complet first-in-man procedur august follow late-
breaker feasibl data present hr complet initi feasibl
studi plan start pivot trial time-frame
product come market expect command substanti
asp premium current landscap well drive meaning share
gain someth factor model
also see return growth icm
franchis launch linq ii probabl hr may
insert cardiac monitor icm space seen growth move
high-teen declin expect declin follow
entri st jude/abbott confirm rx receiv fda approv octob
howev expect launch second gener devic
space like hr roughli around time anoth
competitor might enter us market linq ii wafer scale platform featur
number improv legaci monitor includ extend
batteri life year bluetooth connect better accuracy/artifici
intellig vital sign sensor addit indic
current linq cryptogen stroke syncop atrial fibril linq ii
also util chronic diseas manag af manag heart failur
renal arrhythmia overal help linq platform revert
growth even face addit competit entri
final structur heart lead contend
unpenetr transcathet mitral valv replac tmvr space
intrepid despit impress coapt data present abbott tct
mitraclip mitral repair solut continu believ transcathet
mitral valv replac repair end-goal treat mitral
regurgit reduc mr elimin enrol
compani us trial intrepid mitral valv apollo
began octob intrepid thu far implant via
transap deliveri view transsept solut eventu
necessari widespread commerci adopt given direct tavr
deliveri taken see first-in-human transsept interpid late-
howev compani consid bring french size
deliveri cathet redesign may push first-in-human procedur
time-frame point forecast modest revenu begin
move restor therapi group rtg expect
leverag robot enabl technolog drive spine share gain
largest player difficult flat low-single-digit growth market
spinal implant serial share donor faster-
move innov player space combin constant price
pressur caus spine divis consist dilut overal
growth howev arm innov in-hous robot
offer contain brain therapi expect help compani cross-
sell capit equip platform across rtg addit
core spinal implant expect slow steadi improv includ
modest acceler model next year
brain therapi medtron riptid aspir cathet acut
ischem stroke help off-set share loss flow divers stroke
space receiv fda approv riptid aspir
januari sinc compani enter stroke center
us overal drive major procedur volum
cathet start see traction compani expect launch
version next month broaden address patient popul
us aspir cathet market huge today estim total sale
grow clip annual littl
share current also growth aspir side help off-set impact
competit flow divert side busi
repres overal neurovascular within brain therapi
diabet wont perpetu grow divis continu
accret overal recur revenu larger patient
base high-single-digit better growth possibl last three
quarter medtron diabet group gener north growth help
roll-out novel hybrid-clos loop system associ
high-margin cgm revenu come transit pump patient
anima patient base shut busi octob
 launch stand-alone guardian cgm summer
easi comp initi launch struggl
go forward still expect diabet grow high-single-digit
better rang benefit recur revenu bolu new
patient ad last year half particularli us cgm upgrad
sale transit j/anima patient warranti expir
next month ou launch start
uptak us pediatr patient gain approv
june final upcom launch latter
strive maintain technolog lead hybrid-clos loop
space introduc system automat correct blous someth
tandem plan mid-calendar dont expect product
reveal ada june see sometim cours
minim invas therapi group mitg eye launch
gener surgeri robot time-frame reveal long-
come surgic robot remain event geograph launch locat
remain key question like function time around
regulatori pathway differ market view meaning revenu
opportun like event could see robot come
us view prospect robot still wait-and-se
opportun expect captur end-effector surgic compon share
legaci covidien busi meaning revenu
gener sell capit equip clear isnt posit
better intuit surgic da vinci robot rather way progress open
surgeri still gener surgeri even mi gener surgeri
robot drive greater revenu captur luckili investor
though plan showcas robot us soil investor
modestli rais number establish new price target
upgrad overweight continu forecast organ sale growth
ep report pro-forma
forecast organ sale growth ep
along modestli higher outlook
view conserv given number potenti transform catalyst
next month rais calendar year-end price target
base peer price-to-earnings multipl appli
calendar ep estim result upgrad share
overweight neutral
invest thesi valuat risk
past year weve seen signific turnaround perform
manag deliv four consecut beat rais quarter
top- bottom-lin out-performance return consist exceed
expect importantli materi improv gener
stick point mani investor next month believ
grow least line end-market growth plu see
number underappreci data present transform new product
launch appear fulli appreci street modestli
rais estim conserv leav potenti
catalyst discuss upsid vs forecast manag
appropri set conserv bar top-lin earn progress
june analyst day see meaning upsid street estim potenti
multipl expans sustain execut
along near- mid-term outlook view conserv given
number potenti transform catalyst next month
rais calendar ye price target base peer
price-to-earnings multipl appli calendar ep estim
risk rate price
downsid risk includ slower growth and/or increas competit core end
market slower anticip adopt new technolog poor
deploy capit lack gener
medtron plc summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end apr o/w
analyst certif research analyst denot ac cover report certifi multipl research
analyst primarili respons report research analyst denot ac cover within document
individu certifi respect secur issuer research analyst cover research view
express report accur reflect person view subject secur issuer part
research analyst compens directli indirectli relat specif recommend view
express research analyst report korea-bas research analyst list front cover also certifi per
kofia requir analysi made good faith view reflect opinion without undu influenc
